Browse by author
Lookup NU author(s): Professor Gerard Stansby
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
In this editorial we consider some aspects of the use of clopidogrel in current clinical practice. Clopidogrel has replaced ticlopidine as an alternative to aspirin. Among the problems with the use of antiplatelet agents is aspirin intolerance. The options for these patients are discussed; these include using clopidogrel. Clopidogrel may be especially effective in patients with peripheral arterial disease. However, this impression requires confirmation in appropriately designed trials. We also consider the effect of antiplatelet agents on growth factor release by platelets and of clopidogrel on the inflammatory process. Clopidogrel is a useful, evidence-based, antiplatelet agent.
Author(s): Daskalopoulou SS, Stansby G, Mikhailidis DP
Publication type: Editorial
Publication status: Published
Journal: Current Medical Research and Opinion
Year: 2004
Volume: 20
Issue: 11
Pages: 1835-1838
ISSN (print): 0300-7995
ISSN (electronic): 1473-4877
URL: http://dx.doi.org/10.1185/030079904X10656
DOI: 10.1185/030079904X10656
